Adverse Events Among Patients With Type 2 Diabetes, COVID-19 Treated With Dapagliflozin

July 8, 2021

Conference | ADA

Mikhail Kosiborod, MD, cardiologist and vice president of research at Saint Luke's Health in Kansas City, discussed what some of the adverse events experienced by patients were, and how patients were able to handle them.

Pharmacy Times interviewed Mikhail Kosiborod, MD, cardiologist and vice president of research at Saint Luke's Health in Kansas City, on the results from the DARE-19 trial assessing the efficacy and safety of dapagliflozin in patients with and without type 2 diabetes hospitalized with COVID-19.

During the discussion, Kosiborod addressed what some of the adverse events experienced by patients were, and how patients were able to handle them.